- Home
- RPRX vs H Comparison
RPRX vs H Comparison
Compare RPRX & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- H
- Stock Information
- Founded
- RPRX 1996
- H 1957
- Country
- RPRX United States
- H United States
- Employees
- RPRX N/A
- H N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- H Hotels/Resorts
- Sector
- RPRX Health Care
- H Consumer Discretionary
- Exchange
- RPRX Nasdaq
- H Nasdaq
- Market Cap
- RPRX 14.2B
- H 13.5B
- IPO Year
- RPRX 2020
- H 2009
- Fundamental
- Price
- RPRX $32.20
- H $112.79
- Analyst Decision
- RPRX Strong Buy
- H Buy
- Analyst Count
- RPRX 4
- H 17
- Target Price
- RPRX $42.50
- H $151.65
- AVG Volume (30 Days)
- RPRX 4.5M
- H 1.0M
- Earning Date
- RPRX 05-08-2025
- H 05-01-2025
- Dividend Yield
- RPRX 2.73%
- H 0.53%
- EPS Growth
- RPRX N/A
- H 517.07
- EPS
- RPRX 1.91
- H 12.65
- Revenue
- RPRX $2,263,576,000.00
- H $3,296,000,000.00
- Revenue This Year
- RPRX $31.56
- H $113.96
- Revenue Next Year
- RPRX $5.94
- H $5.79
- P/E Ratio
- RPRX $16.84
- H $8.89
- Revenue Growth
- RPRX N/A
- H N/A
- 52 Week Low
- RPRX $24.05
- H $102.43
- 52 Week High
- RPRX $34.20
- H $168.20
- Technical
- Relative Strength Index (RSI)
- RPRX 51.13
- H 46.08
- Support Level
- RPRX $31.58
- H $102.93
- Resistance Level
- RPRX $32.73
- H $116.32
- Average True Range (ATR)
- RPRX 0.93
- H 5.83
- MACD
- RPRX 0.06
- H 1.18
- Stochastic Oscillator
- RPRX 82.74
- H 58.42
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (4% of total rooms) and managed and franchised (96%) properties across around 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 54% Americas, 22% rest of world, and 23% Asia-Pacific.